Clinical Trial Update: The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy

View source ↗

Summary

The document describes a clinical trial evaluating 68Ga-grazytracer PET to monitor responses to immunotherapy in advanced hepatobiliary malignancy. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatobiliary Cancer

Drugs mentioned

• 68Ga-grazytracer

Snippet

Sponsor: Ruijin Hospital | Conditions: Hepatobiliary Malignancy | Status: RECRUITING